An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.

Purpose: Satraplatin is a third generation oral platinum, which has demonstrated antitumor activity. The aim of this phase I study was to determine the maximum tolerated dose (MTD) of the combination of satraplatin and gemcitabine in patients previously treated with chemotherapy and in patients without prior chemotherapy.

Patients And Methods: Two separate MTDs were planned in two different patient groups (those with and without prior chemotherapy treatment).